Policy Brief 4: Changing from stavudine to tenofovir in first line antiretroviral therapy in South Africa

By Alana Brennan  Kate Shearer  Dr. Matthew Fox  |  | 

Background

Under South Africa’s original public sector antiretroviral therapy (ART) guidelines, introduced in 2004, the antiretroviral drug stavudine (d4T) was one of three antiretroviral drugs (ARVs) that formed the mainstay of first-line treatment. Toxicities associated with stavudine use are common, however, and led to calls to substitute for stavudine a drug with fewer side effects. HERO policy brief 4 — Changing from stavudine to tenofovir – 15 Oct 2012

Publication details

PDF